Phase I Trial of Pirfenidone in Children with Neurofibromatosis 1 and Plexiform Neurofibromas

Pediatric Neurology

Volumn 36, Issue 5, 2007, Pages 293-300

  Babovic Vuksanovic, Dusica ^a   Widemann, Brigitte C ^b   Dombi, Eva ^b   Gillespie, Andrea ^b   Wolters, Pamela L ^b,c   Toledo Tamula, Mary Anne ^b,c   O'Neill, Brian P ^a   Fox, Elizabeth ^b   MacDonald, Tobey ^d   Beck, Heather ^d   Packer, Roger J ^d  

^a Mayo Clinic College of Medicine   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Medical Illness Counseling Center   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; PIRFENIDONE; POTASSIUM;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; AUTOANALYSIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; GRAND MAL SEIZURE; GROUPS BY AGE; HEART PALPITATION; HUMAN; HYPERBILIRUBINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROFIBROMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; SAMPLING; SIDE EFFECT; SYNCOPE; TREATMENT RESPONSE; VOLUMETRY; VOMITING;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; NEUROFIBROMA, PLEXIFORM; NEUROFIBROMATOSIS 1; PYRIDONES; QUALITY OF LIFE; THERAPEUTIC EQUIVALENCY;

EID: 34248177910     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2007.01.009     Document Type: Article

References (17)

1. Korf B.R. Plexiform neurofibromas. Am J Med Genet 89 (1999) 31-37
2. Korf B.R. Malignancy in neurofibromatosis type 1. Oncologist 5 (2000) 477-485
3. Rasmussen S.A., Yang Q., and Friedman J.M. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 68 (2001) 1110-1118
4. Needle M.N., Cnaan A., and Dattilo J. Prognostic signs in the surgical management of plexiform neurofibroma: The Children's Hospital of Philadelphia experience 1974-1994. J Pediatr 131 (1997) 678-682
5. Huson S.M., Harper P.S., and Compston D.A. Von Recklinghausen neurofibromatosis: a clinical and population study in south-east Wales. Brain 111 (1988) 1355-1381
6. Wolkenstein P., Zeller J., Revuz J., Ecosse E., and Leplege A. Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol 136 (2001) 1421-1425
7. Nagai S., Hamada K., Shigematsu M., Taniyama M., Yamauchi S., and Izumi T. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41 (2002) 1118-1123
8. Lindor N.M., Dozois R., Nelson H., et al. Desmoid tumors in familial adenomatous polyposis: a pilot project evaluating efficacy of treatment with pirfenidone. Am J Gastroenterol 98 (2003) 1868-1874
9. Okada Y. Investigational study of clinical indications for pirfenidone ointment. Report from Japan on Human Topical Dermal Trials. Department of Medicine, Maruko Central Hospital, Maruko, Nagano Prefecture, Japan: 1993.
10. Margolin S. Investigational new drug brochure for pirfenidone (2006), Marnac, Inc, Dallas, TX
11. Kadono T., Soma Y., Takehara K., Nakagawa H., Ishibashi Y., and Kikuchi K. The growth regulation of neurofibroma cells in neurofibromatosis type-I: increased responses to PDGF-BB and TGF-β1. Biochem Biophys Res Commun 198 (1994) 827-834
12. Sasaki T., Arai K., and Nagai Y. Growth and collagen synthesis of cultured neurofibroma fibroblasts. J Dermatol 19 (1992) 598-601
13. Babovic-Vuksanovic D., Petrovic L., Knudsen B.E., et al. Survival of human neurofibroma in immunodeficient mice and initial results of therapy with pirfenidone. J Biomed Biotechnol 2004 (2004) 79-85
14. Babovic-Vuksanovic D., Ballman K., Michels V., et al. Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology 67 (2006) 1860-1862
15. Poussaint T., Jaramillo D., Chang Y., and Korf B. Interobserver reproducibility of volumetric MR imaging measurements of plexiform neurofibromas. Am J Roentgenol 180 (2003) 419-423
16. Solomon J., Warren K., Dombi E., Patronas N., and Widemann B. Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput Med Imaging Graph 28 (2004) 257-265
17. Wolters P.L., Martin S.C., Tamula M.A., et al. Development of a quality of life scale for children with chronic illness with CNS involvement: preliminary data. [abstract]. Neurooncology 6 (2004) 448